Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-of-illness of psoriasis - results of a German cross-sectional study.
Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Strömer K, Thaci D, Purwins S, Radtke M, Gutknecht M. Jungen D, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):174-180. doi: 10.1111/jdv.14543. Epub 2017 Sep 26. J Eur Acad Dermatol Venereol. 2018. PMID: 28857297
[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung].
Wolf-Henning B, Friedrich M, Mrowietz U, Reich K, Rosenbach T, Sticherling M, Thaçi D; Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. Wolf-Henning B, et al. Among authors: thaci d. J Dtsch Dermatol Ges. 2003 Aug;1(8):620-8. doi: 10.1046/j.1610-0387.2003.03014.x. J Dtsch Dermatol Ges. 2003. PMID: 16296152 German.
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D. Ortonne JP, et al. Among authors: thaci d. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20. doi: 10.1111/j.1468-3083.2010.03944.x. Epub 2011 Jan 9. J Eur Acad Dermatol Venereol. 2011. PMID: 21214631 Clinical Trial.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Paul C, et al. Br J Dermatol. 2014 Feb;170(2):425-34. doi: 10.1111/bjd.12646. Br J Dermatol. 2014. PMID: 24116959 Free article. Clinical Trial.
306 results